Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

J. Rafael Sierra, Virna Cepero, Silvia Giordano

Research output: Contribution to journalArticlepeer-review


In recent years, tyrosine kinases (TKs) have been recognized as central players and regulators of cancer cell proliferation, apoptosis, and angiogenesis, and are therefore considered suitable potential targets for anti-cancer therapies. Several strategies for targeting TKs have been developed, the most successful being monoclonal antibodies and small molecule tyrosine kinase inhibitors. However, increasing evidence of acquired resistance to these drugs has been documented, and extensive preclinical studies are ongoing to try to understand the molecular mechanisms by which cancer cells are able to bypass their inhibitory activity. This review intends to present the most recently identified molecular mechanisms that mediate acquired resistance to tyrosine kinase inhibitors, identified through the use of in vitro models or the analysis of patient samples. The knowledge obtained from these studies will help to design better therapies that prevent and overcome resistance to treatment in cancer patients.

Original languageEnglish
Article number75
JournalMolecular Cancer
Publication statusPublished - Apr 12 2010

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology


Dive into the research topics of 'Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy'. Together they form a unique fingerprint.

Cite this